10 Medications with Lower Prices in 2026: Find Out If Yours Is on the List

In 2026, millions of Americans are expected to pay significantly less for prescription drugs thanks to a landmark federal effort to negotiate lower drug prices under the Inflation Reduction Act. The 2026 drug price cuts affect some of the most commonly used medications, offering Medicare medication discounts, reduced out-of-pocket spending, and real healthcare savings for seniors and people with chronic conditions. Here’s a look at the list of medications with new negotiated prices and how these cuts may help you save.

A row of prescription medication bottles with a bold “2026 Reduced Prices” banner graphic overlaid, arranged on a pharmacy countertop with clear labels, modern realistic lighting, no brand logos.

What Is the Medicare Drug Price Negotiation Program?

For the first time, the Centers for Medicare & Medicaid Services (CMS) has negotiated prices with pharmaceutical companies for certain high-cost drugs covered under Medicare Part D — the prescription drug benefit for Medicare enrollees. This process, authorized by the Inflation Reduction Act, aims to lower the maximum fair prices (MFPs) of certain drugs and reduce Medicare pharmacy costs in 2026.

These negotiations focus on brand-name drugs with no generic or biosimilar competition — often those with the highest overall costs to Medicare. The negotiated prices take effect beginning January 1, 2026 and represent some of the most meaningful federal efforts yet to curb rising drug prices.

Medications Slashed in Price for 2026

CMS selected the first group of 10 drugs for price negotiation under the 2026 program. These medications treat conditions such as diabetes, heart failure, blood clots, autoimmune diseases, and more. Below are the negotiated drugs now subject to 2026 negotiated price discounts:

  1. Eliquis (apixaban) – A widely used blood thinner to prevent and treat blood clots. Negotiated prices are significantly lower than previous list prices.
  2. Jardiance – A diabetes and heart failure medication.
  3. Xarelto – Another anticoagulant used to reduce clot risk.
  4. Januvia – Diabetes treatment now available at a negotiated lower cost.
  5. Farxiga – Used for diabetes, heart failure, and chronic kidney disease.
  6. Entresto – A heart failure medication with new price reductions.
  7. Enbrel – Treats rheumatoid arthritis and psoriasis.
  8. Imbruvica – A treatment for blood cancers.
  9. Stelara – Used for psoriasis and certain inflammatory bowel diseases.
  10. NovoLog / Fiasp – Rapid-acting insulin types used to manage blood glucose levels.

These medications represent some of the most expensive and widely used drugs under Medicare Part D, and their negotiated prices represent a new benchmark for government-backed drug cost containment.

How Much Can You Save?

The negotiated discounts are significant — some ranging from about 38% to 79% off previous list prices for the 10 targeted drugs. By lowering these prices, CMS projects that Medicare beneficiaries could collectively save as much as $1.5 billion in out-of-pocket costs in 2026, with broader savings for taxpayers as well.

For example, earlier reporting on insulin price changes highlights how some diabetes medications (like Januvia) saw dramatic price reductions — approximately a 79% drop on a 30-day supply — due to these negotiations.

Why This Matters to Medicare Beneficiaries

Medicare Part D enrollees often face high co-pays or coinsurance for brand-name drugs. By placing limits on how much manufacturers can charge for selected medications, the program helps reduce Medicare pharmacy costs and provides Medicare savings in 2026 for people managing chronic conditions such as diabetes, heart disease, and autoimmune disorders.

While these negotiated prices are specific to Medicare enrollees, they signal a broader shift in U.S. healthcare policy toward price transparency and affordability, prompting other insurers and drug pricing initiatives to consider similar strategies.

What’s Next: Future Price Negotiations

The negotiation program is set to continue beyond 2026, with additional drugs being selected for future price cuts. For example, the next round of price negotiations, affecting 15 major medications (potentially including diabetes and cancer treatments), is scheduled to take effect in 2027.

This continued expansion could widen affordability and lower Medicare medication discounts even further for more Americans in the coming years.

Conclusion: The 2026 drug price cuts represent a historic shift in U.S. drug pricing policy, with lower prices on a negotiated list of 10 medications affecting common conditions such as diabetes, heart disease, autoimmune disorders, and more. If you or a loved one are on any of these drugs, you may see meaningful savings starting in 2026. Keep an eye on future CMS negotiation rounds, as more price drop meds could be added in subsequent years.